New centre to offer 'real hope' for cancer patients

Cancer care in Western Australia is set to advance to another level with the launch of a new centre in the campus of Australia's largest private hospital.

Icon Cancer Centre's new joint venture will be the first of its kind in the state, providing patients with comprehensive theranostics and molecular imaging services which are changing the way the disease is treated.

Icon, the country's leading dedicated provider of cancer care services, has teamed up with Perth Molecular Imaging and Theranostics Centre (PMITC).

The centre, expected to open by the end of 2025, will be based at the Hollywood Medical Centre adjacent to Hollywood Private Hospital.

"This comprehensive centre represents the future of personalised cancer care and marks a major step forward in improving access to cutting-edge theranostics, which offer real hope for people with advanced and metastatic cancers," said Icon's Clinical Director of Molecular Imaging and Nuclear Oncology, Dr Nat Lenzo.

While theranostics services are available in Western Australia, this marks the first dedicated centre with all imaging services under one roof centrally located.

It helps to meet the growing need for molecular imaging and therapy services, and being based so close to Ramsay Health Care's flagship private hospital makes it easier for more people across the state to receive the care they need.

"By offering patients access to a full suite of imaging and precision medicine treatments under one roof we're improving the patient experience and ensuring we can better support people and their families through a difficult time without the need to travel far distances," Dr Lenzo said.

Dr Nat Lenzo, Icon's Clinical Director of Molecular Imaging and Nuclear Oncology

The new Icon Cancer Centre will deliver an integrated private service combining advanced PET-CT and SPECT-CT imaging, targeted radiopharmaceutical therapies, including theranostics, and access to global clinical trials enhancing access to precision medicine for local, interstate, and international patients.

Theranostics is a growing area of medicine that combines advanced diagnostic imaging with highly-targeted treatment.

It identifies a person's unique cancer cells and delivers personalised targeted therapy to the diseased tissue, aiming to slow its growth and spread, relieve symptoms and maintain or improve quality of life.

Theranostics may be considered for people with advanced cancer, when standard treatment options are unsuitable or no longer effective and symptoms are affecting quality of life.

"Theranostics is changing the way we treat cancer," Dr Lenzo said.

"We're giving patients more therapy options and seeing great results.

"It's highly personal targeted treatment resulting in fewer long-term side-effects and better outcomes – so patients are living longer and able to spend more quality time with loved ones."

The centre will be the first in the state to be equipped with Siemens Healthineers' Biograph Trinion PET-CT scanner.

Its array of highly-advanced imaging technology will support diagnosis, staging and treatment of conditions including prostate cancer and neuroendocrine tumours, as well as new and developing uses in neurology and cardiology.

Icon, which launched its first theranostics service at Icon Cancer Centre North Lakes in Brisbane, expects the new clinic to complement its other Perth facilities in Rockingham and Midland.

Read more: 'New hope' for cancer patients

Read more: Icon partnership opens access to advanced cancer care

Next Safety And Quality:
4/9/2025 Australian-first scanner helps prostate patients

Previous Safety And Quality:
9/7/2025 Learning calm in the chaos of Emergency Care